Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study

What Was Tested

The paper reports a study of Liraglutide, published as a clinical trial.

The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD).

Hemodialysis was conducted on days 1 and 3.

Who Took Part

According to the abstract, 2 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as pilot.

It is described as a pilot, a small early test of whether a larger Liraglutide study would be practical.

Plasma liraglutide and glucose concentrations were measured by enzyme-linked immunosorbent assay and a continuous glucose monitoring system, respectively.

What Was Measured

The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD).

The safety profile of liraglutide was also assessed.

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Kidney Failure, Chronic, Liraglutide, Pilot Projects and Renal Dialysis.

What This Means in Plain Language

The paper is a pilot study of Liraglutide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2014 (PloS one), a journal based in United States.

More context: the Liraglutide compound page, all human trials.